Recall events
/
Event 87751
Event summary
Timeline bucket March 31, 2021
Product types Drug
Classifications Class II
Statuses Ongoing
Recalling firm wording QMart
Dossier provenance
Source snapshots represented here
openFDA Drug Enforcement
Report-date coverage
June 20, 2012–July 08, 2026
Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.
Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.
How coverage and grouping work
Device root-cause evidence is not applicable to this event.
No grouped product has the official product type device; this is not an unavailable-enrichment finding.
Complete imported group
Every recalled product in this event
4 official enforcement rows
Product dates, classifications, firms, and source wording remain attached to their individual rows.
Opening this dossier never hides products that did not match a prior timeline filter.
drug · product 1 of 4
IMPERIAL GOLD 2000, Male Sexual Performance Enhancement, 1 Capsule, UPC 718122040702
D-0368-2021
Recall number D-0368-2021
Initiated March 31, 2021
Classification Class II
Status Ongoing
Quantity 200 boxes
App-derived interpretation
Unknown
reason.no_named_rule · v1.0.0
Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil and/or sildenafil.
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil and/or sildenafil.
Distribution pattern USA Nationwide
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[12958]
FDA event record
· Exact recall-number query on openFDA
drug · product 2 of 4
PremierZen Extreme 3000, Male Sexual Performance Enhancement, 1 Capsule, UPC 728175421887
D-0369-2021
Recall number D-0369-2021
Initiated March 31, 2021
Classification Class II
Status Ongoing
Quantity 500 boxes
App-derived interpretation
Unknown
reason.no_named_rule · v1.0.0
Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil and/or sildenafil.
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil and/or sildenafil.
Distribution pattern USA Nationwide
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[12479]
FDA event record
· Exact recall-number query on openFDA
drug · product 3 of 4
Burro en Primavera, 2 capsules, UPC 638632431055
D-0370-2021
Recall number D-0370-2021
Initiated March 31, 2021
Classification Class II
Status Ongoing
Quantity 500 boxes
App-derived interpretation
Unknown
reason.no_named_rule · v1.0.0
Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil and/or sildenafil.
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil and/or sildenafil.
Distribution pattern USA Nationwide
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[12231]
FDA event record
· Exact recall-number query on openFDA
drug · product 4 of 4
Imperial Platinum 2000, 1 capsule, UPC 718122040702
D-0371-2021
Recall number D-0371-2021
Initiated March 31, 2021
Classification Class II
Status Ongoing
Quantity 200 boxes
App-derived interpretation
Unknown
reason.no_named_rule · v1.0.0
Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil and/or sildenafil.
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil and/or sildenafil.
Distribution pattern USA Nationwide
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[12393]
FDA event record
· Exact recall-number query on openFDA
